wings4innovation and KHAN-I technology transfer fund provide a new translation and financing paradigm for innovative drug discovery proposals from Austrian academic institutes and SMEs. wings4innovation GmbH (w4i) is a subsidiary of KHAN Technology Transfer Fund I GmbH & Co. KG (KHAN-I). KHAN-I was set up jointly by Austria Wirtschaftsservice (aws), European Investment Fund (EIF) and the Max Planck Foundation to support the translation of excellent basic research into drug development projects. w4i scouts and evaluates project ideas and proposes suitable projects for KHAN-I funding. w4i is the central contact for academic/SME partners from all over Austria. Call for Proposals: Researchers from Austrian academic institutes can apply with their ideas until the end of 2023. We are scouting for project ideas with a clear hypothesis for an innovative therapy in indications with a high unmet need.